As Accelerate Diagnostics INC (AXDX) Market Valuation Declined, Oracle Investment Management INC Lifted Its Holding

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) LogoInvestors sentiment increased to 1.57 in 2019 Q2. Its up 0.44, from 1.13 in 2019Q1. It increased, as 10 investors sold AXDX shares while 20 reduced holdings. 14 funds opened positions while 33 raised stakes. 27.92 million shares or 7.98% more from 25.86 million shares in 2019Q1 were reported. Barclays Public Limited Com, a United Kingdom-based fund reported 67,131 shares. National Bank Of America Corp De holds 0% or 66,716 shares. Selkirk Management Ltd holds 4.29% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for 348,805 shares. Essex Investment Co Limited Liability Company reported 67,250 shares. Synovus owns 0% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for 1,636 shares. Oz Lp has 0.01% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for 56,800 shares. 5,750 are held by Sg Americas Secs Ltd Liability Company. D E Shaw stated it has 27,799 shares or 0% of all its holdings. Hightower Advisors reported 12,687 shares. Northwestern Mutual Wealth Mgmt Com accumulated 0% or 604 shares. C Group Inc Holdings A S invested 0.15% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Cutter & Brokerage Inc has invested 0.15% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). 1.76M are held by Axa. California Pub Employees Retirement Systems reported 0% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 1,750 shares.

Oracle Investment Management Inc increased its stake in Accelerate Diagnostics Inc (AXDX) by 2010.64% based on its latest 2019Q2 regulatory filing with the SEC. Oracle Investment Management Inc bought 4.15M shares as the company’s stock declined 4.21% . The hedge fund held 4.36M shares of the capital goods company at the end of 2019Q2, valued at $99.67 million, up from 206,400 at the end of the previous reported quarter. Oracle Investment Management Inc who had been investing in Accelerate Diagnostics Inc for a number of months, seems to be bullish on the $1.12B market cap company. The stock increased 0.79% or $0.16 during the last trading session, reaching $20.48. About 230,133 shares traded or 20.57% up from the average. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has declined 10.62% since September 13, 2018 and is downtrending. It has underperformed by 10.62% the S&P500.

Oracle Investment Management Inc, which manages about $877.33M and $464.87M US Long portfolio, decreased its stake in Quidel Corp (NASDAQ:QDEL) by 118,294 shares to 1.79 million shares, valued at $105.90M in 2019Q2, according to the filing.

More notable recent Accelerate Diagnostics, Inc. (NASDAQ:AXDX) news were published by: Seekingalpha.com which released: “Accelerate Diagnostics, Inc. (AXDX) CEO Lawrence Mehren on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” on February 19, 2019, also Nasdaq.com with their article: “Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates – Nasdaq” published on August 08, 2019, Seekingalpha.com published: “Accelerate Diagnostics (AXDX) Presents At Cowen and Company 39th Annual Health Care Conference – Slideshow – Seeking Alpha” on March 13, 2019. More interesting news about Accelerate Diagnostics, Inc. (NASDAQ:AXDX) were released by: Finance.Yahoo.com and their article: “Did Hedge Funds Drop The Ball On Accelerate Diagnostics Inc (AXDX) ? – Yahoo Finance” published on May 08, 2019 as well as Seekingalpha.com‘s news article titled: “Wall Street Brunch – Seeking Alpha” with publication date: August 18, 2019.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.